User login
Key clinical point: The short-term risk for cancer other than non-melanoma skin cancer (NMSC) or NMSC was not significantly higher among patients with psoriatic arthritis (PsA) who initiated Janus kinase inhibitors (JAKi) than those who initiated tumor necrosis factor inhibitors (TNFi).
Major finding: JAKi vs TNFi was not significantly associated with a higher risk for cancer other than NMSC (adjusted hazard ratio [aHR] 1.88; 95% CI 0.68-5.16) or NMSC (aHR 2.05; 95% CI 0.79-5.31) in patients with PsA.
Study details: The data come from an observational cohort study that evaluated prospectively collected data of 4443 patients with PsA and 10,447 patients with RA, all without previous cancer, who received JAKi, TNFi, or other non-TNFi biologic disease-modifying antirheumatic drugs.
Disclosures: This study was funded by the Karolinska Institute Region Stockholm funds (ALF), Swedish Research Council, and others. T Frisell and H Bower declared being partly employed by the ARTIS project. J Askling reported research agreements with various sources.
Source: Huss V et al on behalf of the ARTIS group. Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: A national real-world cohort study. Ann Rheum Dis. 2023 (Mar 3). Doi: 10.1136/ard-2022-223636
Key clinical point: The short-term risk for cancer other than non-melanoma skin cancer (NMSC) or NMSC was not significantly higher among patients with psoriatic arthritis (PsA) who initiated Janus kinase inhibitors (JAKi) than those who initiated tumor necrosis factor inhibitors (TNFi).
Major finding: JAKi vs TNFi was not significantly associated with a higher risk for cancer other than NMSC (adjusted hazard ratio [aHR] 1.88; 95% CI 0.68-5.16) or NMSC (aHR 2.05; 95% CI 0.79-5.31) in patients with PsA.
Study details: The data come from an observational cohort study that evaluated prospectively collected data of 4443 patients with PsA and 10,447 patients with RA, all without previous cancer, who received JAKi, TNFi, or other non-TNFi biologic disease-modifying antirheumatic drugs.
Disclosures: This study was funded by the Karolinska Institute Region Stockholm funds (ALF), Swedish Research Council, and others. T Frisell and H Bower declared being partly employed by the ARTIS project. J Askling reported research agreements with various sources.
Source: Huss V et al on behalf of the ARTIS group. Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: A national real-world cohort study. Ann Rheum Dis. 2023 (Mar 3). Doi: 10.1136/ard-2022-223636
Key clinical point: The short-term risk for cancer other than non-melanoma skin cancer (NMSC) or NMSC was not significantly higher among patients with psoriatic arthritis (PsA) who initiated Janus kinase inhibitors (JAKi) than those who initiated tumor necrosis factor inhibitors (TNFi).
Major finding: JAKi vs TNFi was not significantly associated with a higher risk for cancer other than NMSC (adjusted hazard ratio [aHR] 1.88; 95% CI 0.68-5.16) or NMSC (aHR 2.05; 95% CI 0.79-5.31) in patients with PsA.
Study details: The data come from an observational cohort study that evaluated prospectively collected data of 4443 patients with PsA and 10,447 patients with RA, all without previous cancer, who received JAKi, TNFi, or other non-TNFi biologic disease-modifying antirheumatic drugs.
Disclosures: This study was funded by the Karolinska Institute Region Stockholm funds (ALF), Swedish Research Council, and others. T Frisell and H Bower declared being partly employed by the ARTIS project. J Askling reported research agreements with various sources.
Source: Huss V et al on behalf of the ARTIS group. Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: A national real-world cohort study. Ann Rheum Dis. 2023 (Mar 3). Doi: 10.1136/ard-2022-223636